Centre intensifies regulatory surveillance over weight loss drugs

To ensure ethical pharmaceutical practices in the supply chain of weight loss drug (GLP-1), the Drugs Controller of India has intensified its regulatory surveillance against the drug’s unauthorised sale and promotion.

“With the recent introduction of multiple generic variants of GLP-1-based weight loss drugs in the Indian market, concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and wellness clinics. These drugs, when used without proper medical supervision, may lead to serious adverse effects and related health risks,’’ said the Health Ministry in a release on Tuesday (March 24, 2026).

Taking cognisance of the situation, India’s drugs controller, in collaboration with State regulators, has initiated a series of targeted actions to curb possible malpractices across the pharmaceutical supply chain and prevent unauthorised sales and use.